Daprodustat: A potential game-changer in renal anemia therapy—A perspective

The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD’s efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD a...

Descripción completa

Detalles Bibliográficos
Autores principales: Haider, Muhammad Usman, Furqan, Muhammad, Mehmood, Qasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449327/
https://www.ncbi.nlm.nih.gov/pubmed/37637409
http://dx.doi.org/10.3389/fphar.2023.1249492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449327/
https://www.ncbi.nlm.nih.gov/pubmed/37637409
http://dx.doi.org/10.3389/fphar.2023.1249492

Ejemplares similares